SCHEMBL5234599

SCHEMBL5234599

Cn1nc(C2CCCCC2)c2c(=O)[nH]c(-c3ccc(N)cc3)nc21

nearest known ligand 0.69

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 4/20 0.69
PDE7B Q9NP56 1/20 0.43
ADORA2B P29275 3/20 0.40
ADORA1 P30542 1/20 0.40
PDE5A O76074 3/20 0.40
ADORA2A P29274 2/20 0.39
PARP1 P09874 5/20 0.38
TNKS O95271 4/20 0.38
TNKS2 Q9H2K2 4/20 0.38
GRIA1 P42261 1/20 0.36
GRIA2 P42262 1/20 0.36
GRIA3 P42263 1/20 0.36
GRIA4 P48058 1/20 0.36
PDE4D Q08499 1/20 0.36
DRD1 P21728 1/20 0.36
DRD5 P21918 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5233086 0.89 PDE7A (0.58) PDE7AADORA2BPDE5AADORA2APARP1
SCHEMBL5237929 0.89 PDE7A (0.60) PDE7AADORA2BADORA1PDE5AADORA2A
SCHEMBL5230233 0.86 PDE7A (0.55) PDE7AADORA2BADORA1PDE5AADORA2A
SCHEMBL5233335 0.84 PDE7A (0.54) PDE7APDE7BPARP1TNKSTNKS2
SCHEMBL5229882 0.83 PDE7A (0.53) PDE7APDE7BPARP1TNKSTNKS2
SCHEMBL5231499 0.82 PDE7A (1.00) PDE7APDE7BPDE5APDE4D
SCHEMBL5235905 0.80 PDE7A (0.49) PDE7AADORA2BPDE5A
SCHEMBL5271046 0.80 PDE7A (0.49) PDE7APDE7BPARP1TNKSTNKS2
SCHEMBL5237498 0.80 PDE7A (0.49) PDE7APDE7B
SCHEMBL5230592 0.79 PDE7A (0.49) PDE7AADORA2BADORA1PDE5AADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1454897-B1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY ASUBIO PHARMA CO LTD (JP) 2007-10-10 EP disclosed
EP-1454897-B1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY ASUBIO PHARMA CO LTD (JP) 2007-10-10 EP disclosed
US-7268128-B2 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action AUSBIO PHARMA CO., LTD. (JP) 2007-09-11 US disclosed
US-7268128-B2 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action AUSBIO PHARMA CO., LTD. (JP) 2007-09-11 US disclosed
US-7268128-B2 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action AUSBIO PHARMA CO., LTD. (JP) 2007-09-11 US disclosed
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action OMEROS CORPORATION 2005-07-07 US disclosed
EP-1454897-A1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY Daiichi Suntory Pharma Co., Ltd. (JP) 2004-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action PDE7B, PDE3B, PDE3A PDE7A 4/4885PDE7B 1/4885ADORA2B 667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.